Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Transactions in connection with share buy-back programme

On 4 March 2021, H+H International A/S (hereinafter referred to as “H+H” or “the Company”) initiated a share buy-back programme in compliance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on Market Abuse and Commission Delegated Regulation (EU) 1052/2016 of 8 March 2016 (the “Safe Harbour Regulation”). On 18 March 2021, the share buy-back programme was increased by DKK 15 million, thereby increasing the maximum aggregate purchase price of the shares to be bought back under the programme to DKK 115 million. The share buy-back

BioStock: Several triggers for Pila Pharma in 2022

There is no doubt that type 2 diabetes has become one of the most common diseases with more than half a billion people affected, according to t International Diabetes Federation. Malmö company Pila Pharma with CEO Dorte X Gram develops a new approach, and, since July 2021, the company’s shares are listed on Nasdaq First North Growth Market. Several milestones have already been reached, and there will be several potential triggers for the stock in 2022.Read the full article at biostock.se:https://www.biostock.se/en/2022/01/several-triggers-for-pila-pharma-in-2022/This is a press release

Cereno Scientific obtains additional patent protection for Phase II drug candidate CS1 in Japan

Cereno Scientific (XSAT: CRNO B) today announced strengthening of intellectual property rights (IPR) for drug candidate CS1 in the major market Japan. The patent is part of the third patent family which now has protection in Russia as well as Japan. It adds to the growing IPR portfolio for CS1 covering almost all global markets.“The expansion of CS1’s patent protection in Japan is an important step in our efforts to protect our innovations and strengthen the commercial positioning of the drug candidate. Japan is one of the largest pharmaceutical markets in the world and it is therefore key

Idogen publishes interim report for 1 January – 31 December 2021

Idogen AB's interim report for January to December 2021 is available on the company's website https://idogen.com/en/investors/financial-reports/   Fourth quarter (October- December 2021) • Other operating income amounted to KSEK 3,335 (1,949) • Operating loss was KSEK -13,552 (-7,449) • Loss for the quarter totalled KSEK -13,529 (-7,897) • Cash flow from operating activities was KSEK -15,074 (-10,428) • Loss per share before dilution was SEK -0.61 (-0.74). Loss per share after dilution was SEK -0.61 (-0.74) • The proposed dividend is SEK 0.00/share (0.00)

Imfinzi improves survival in biliary tract cancer

19 January 2022 07:05 GMT Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer TOPAZ-1 is the first Phase III trial to show improved survivalwith an immunotherapy combination in this setting Combination did not increase discontinuations due to adverse events vs. chemotherapy alone Positive results from the TOPAZ-1 Phase III trial showed AstraZeneca's Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and

Invitation to Bulten’s Capital Markets Day 2022

Bulten invites analysts, investors and media to a digital Capital Markets Day on Tuesday, February 22, 2022 at 13:30-16:00 (CET).The purpose of the afternoon is to give an update on Bulten’s strategy for sustainable growth, financial development and focus areas. Presentations will be held by Anders Nyström, President and CEO, Markus Baum, Chief Commercial Officer, Emmy Pavlovic, SVP Technology and Innovation, Fredrik Bäckström, Chief Operating Officer, Claes Lindroth, SVP Purchasing and Quality, and Anna Åkerblad, CFO. Due to Covid-19, the event will be held as a webcast.  Date: Tuesday,

Bluestep Bank AB (publ) signs UN Principles for Responsible Banking

19, January, Stockholm. Bluestep Bank AB (publ) has become an official Signatory of the UN Principles for Responsible Banking – a single framework for a sustainable banking industry developed through a partnership between banks worldwide and the United Nations Environment Programme Finance Initiative (UNEP FI).  The Principles are the leading framework for ensuring that banks’ strategies and practices align with the vision society has set out for its future in the UN Sustainable Development Goals and the Paris Climate Agreement. Banks who have signed the Principles commit to be ambitious

Atea recognized among global leaders in sustainability

Atea’s sustainability efforts have earned first-time recognition and ranking by the  globally respected research and media company, Corporate Knights. In their newly published Global 100 Index 2022, Atea is ranked as the world’s most sustainable company in the IT Services Division and 51[st] overall - assessed out of a list of some 6,914 corporations with more than $1B in revenue. Atea CEO Steinar Sønsteby greeted this global ranking: “It is a great honor to be recognized by Corporate Knights as a global leader in sustainability. At Atea, we’re committed to performance, not just promises,

Imfinzi combo shows unprecedented survival in HCC

19 January 2022 07:00 GMT Imfinzi plus tremelimumab demonstrated unprecedented survival in 1st-line unresectable liver cancer with 31% of patients alive at three years A single priming dose of tremelimumab plus Imfinzi every fourweeks reduced risk of death by 22% in HIMALAYA Phase III trial Combination also showed no increase in severe liver toxicity and fewerdiscontinuations due to treatment-related adverse events vs. sorafenib Positive results from the HIMALAYA Phase III trial showed a single priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a

MAG Interactive AB (publ) publishes Interim Report September – November 2021/2022

MAG shows double digit growth for the ninth consecutive quarter thanks to continued improvements of the evergreen games in its portfolio. Net sales grew by 11%, and ARPDAU increased by 38% compared to Q1 the previous year.Summary of the period September 2021 – November 2021: · The Group's net sales for the period were 69,838 KSEK (62,950 KSEK), an increase of 11% compared to the same period the previous year · EBITDA for the period was 17,133 KSEK (9,290 KSEK) · Adjusted EBITDA for the period was 16,343 KSEK (9,349 KSEK) (adjustments for EBITDA relate to effects from acquisition

SciBase announces a change in the Management team and new head of Quality and Regulatory Affairs.

SciBase has appointed Alf Laurell as Director of Quality Assurance and Regulatory Affairs and Person for Regulatory Compliance (PRRC) for SciBase. Alf joins SciBase from Elekta in Stockholm. The previous head of Quality and Regulatory and PRRC, Niklas Jakobsson has decided to pursue a new opportunity outside the company and as such leaves the SciBase Management team.”I would like to warmly welcome Alf to SciBase, and look forward to working with him. I would also like to take the opportunity to thank Niklas for his exceptional work at SciBase, and especially his work with the new Medical

Peab rebuilds E22 outside Karlskrona

Peab has been commissioned to rebuild E22 between Lösen and Jämjö outside of Karlskrona. The customer is the Swedish Transport Administration and the contract is worth SEK 745 million.A 15 kilometer stretch of the road between Lösen and Jämjö will be rebuilt into a freeway to improve traffic safety and passability. The current standard of the road is considered low for the amount of traffic on it. This will also improve the residential environment in Jämjö since through traffic will be transferred to outside the city and more noise barriers will be erected along this stretch of road.

NENT Group named top sustainability performer by Sustainalytics

· NENT Group recognised as a ‘Top-Rated’ sustainability performer in both its industry and region · Company ranked 10[th] out of 299 businesses in global media industry · NENT Group recently included in S&P Dow Jones Sustainability Indices for the world and Europe Nordic Entertainment Group (NENT Group) has been recognised as a leading sustainability performer by Sustainalytics, a global sustainability research, ratings and data firm. Following analysis of more than 4,000 companies around the world, Sustainalytics has awarded NENT Group a 2022 Industry Top-Rated Badge as well as a

DIAN-TU enrolls first subject for the Tau NexGen study with lecanemab as back-ground anti-amyloid treatment

Stockholm, January 19, 2022 - BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has enrolled the first subject in the phase II/III study (Tau NexGen study). The study will assess the safety, tolerability, biomarker and cognitive efficacy of investigational tau-therapies in pre-symptomatic or symptomatic participants who have an Alzheimer’s disease-causing gene mutation, while using BioArctic and Eisai’s investigational anti-amyloid

Multiconsult acquires Smidt & Ingebrigtsen AS

Multiconsult ASA (OSE: MULTI) acquires Smidt & Ingebrigtsen AS and strengthens its competence and market position in western Norway.Smidt & Ingebrigtsen is a consulting engineering company based in Bergen, with a strong reputation and a solid market position both in the public and private construction and civil engineering market in western Norway. Smidt & Ingebrigtsen revenues for 2020 was NOK 19 million and has seven employees who will be joining Multiconsult. The two companies have had a close and good collaboration in the past and are now looking forward to continuing the good

Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty

Lund, Sweden, January 19, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the initiation a sponsored research collaboration to study biomarker data from Alligator´s OPTIMIZE-1 study with the University of Pennsylvania’s (UPENN) Pancreatic Cancer Research Center. Gregory Beatty, MD, PhD, assistant professor of Medicine in the Division of Hematology/Oncology, UPENN, will serve as the faculty investigator for the sponsored Research agreements. Data analysis by Dr. Beatty and his team will be conducted at the Beatty Laboratory  at UPENN.

Tietoevry unveils renewed brand and identity – six specialized businesses operational with new names

Following the new strategy announced in October, Tietoevry kicks off the year unveiling a renewed brand and identity where technology, humanity and responsibility are at the core. The six new specialized businesses, operational since 1[st] of January, are also renamed to reflect their distinct focus and market position. Tietoevry kick-starts the next phase for the company and unveils a renewed brand and identity to position itself for the future. The core of the brand and identity is the new purpose: “Creating purposeful technology to reinvent the world for good”. “Our new purpose

Nokian Tyres will publish its Financial Statement Release 2021 on February 8, 2022

Nokian Tyres plc Press Release January 19, 2022, 9:00 a.m. Nokian Tyres will publish its Financial Statement Release 2021 on February 8, 2022 approximately at 2:00 p.m. EET. After publication, the release and presentation material will be available on the company's website at www.nokiantyres.com/company/investors/. Conference call A conference call for investors, analysts and media will be held on February 8 at 3:00 p.m. EET. In the call, President and CEO Jukka Moisio and CFO Teemu Kangas-Kärki will present the financial results. To participate, please dial in 5−10 minutes

Elisa: Q4 Interim Report and Financial Statements Release 2021 publication on 27 January 2022

ELISA CORPORATION INVESTOR NEWS 19 JANUARY 2022 AT 8:30 AMElisa will publish its Q4 2021 Interim Report and Financial Statements Release 2021 on Thursday 27 January 2022 at approximately 8:30 am EET (6:30 UK time). International conference call for analysts and investors will be held on the same day at 12:00 pm EET. Dial-in numbers for the conference call, PIN: 56942664# · FI: +358 981 710 310 · SE: +46 856 642 651 · UK: +44 333 300 0804 · US: +1 631 913 1422 Audiocast: https://elisa.videosync.fi/financial-results-2021 The presentations will be available on elisa.

Aqilion strengthens its operational team in preclinical development

Aqilion announced today that Anneli Hällgren has been appointed the new head of preclinical development, including regulatory safety studies. Anneli has worked for the past ten years as a consultant in preclinical drug discovery and will now join the Aqilion team on a part-time basis. Anneli Hällgren holds a PhD in physiology from Uppsala University, Sweden, and has more than 20 years of experience in research and development projects with a focus on a variety of indications and disease areas, including inflammatory and autoimmune conditions. Her career began at AstraZeneca, where she

Invitation to presentation of the fourth quarter and full year 2021 results

Stockholm – Tele2 AB (“Tele2”) (Nasdaq Stockholm: TEL2 A and TEL2 B) will publish its Q4 and full year 2021 results on Tuesday, 1 February 2022. The presentation will be hosted by Kjell Johnsen, President and CEO, Charlotte Hansson, EVP Group CFO, Hendrik de Groot, EVP Chief Commercial Officer, Stefan Trampus EVP B2B and Patrik Johannesson, Interim Head of Investor Relations.Tele2 will publish its financial results for Q4 and full year 2021 at 07:00 CET (06:00 GMT, 01:00 EST) on Tuesday, 1 February 2022. Teleconference and webcastTele2 will host a teleconference and webcast with

Swedbank Economic Outlook: the Riksbank picks up the pace

Higher inflation is expected to lead the Riksbank to tighten its monetary policy and raise the repo rate twice next year. The first rate hike will take place in the beginning of 2023, according to the forecast in Swedbank Economic Outlook.The pandemic has once again gripped the Swedish economy, and restrictions have been reintroduced. Despite this, economic growth will be stronger than normal during the coming years. Increased infection rates and high energy prices are dampening growth prospects in the near term but are not expected to lead to any lasting effects. “Economic activity in

EQT AB (publ) Year-end Report 2021

Building on our strengths“While the pandemic continued to impact our lives throughout 2021, vaccines were developed and rolled out at a record pace. Geopolitical tensions loomed, but we also saw nations come together to agree to the Glasgow Climate Pact at COP26. Market conditions were conducive, but we are seeing possible signs of a softer macro environment. Against this backdrop, EQT has continued to build on its strengths and delivered the best year in its history on almost every metric. Our growth journey is evident in the figures for the full year, as well as in our ambitions

Neste included in the Corporate Knights 2022 Global 100 Index for the 16th consecutive time

Neste Corporation, Press Release, 19 January 2022 at 07:15 a.m. (EET)Neste has been included in the Corporate Knights 2022 Global 100 Index  of the most sustainable companies in the world for the 16th consecutive time. Neste has been included in the index for longer than any other energy company in the world. In 2022, Neste placed 24th in the index and first among its industry peers.In the 2022 index, Corporate Knights introduced a new methodology in

There are no items matching the current filter
There are no more items matching the current filter
Back to top